Linezolid chemical structure
Find information on thousands of medical conditions and prescription drugs.

Zyvox

Linezolid is a synthetic systemic antibiotic drug. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

It was the first commercially available oxazolidinone antibiotic and is usually reserved for the treatment of serious bacterial infections where older antibiotics have failed due to antibiotic resistance. Conditions such as skin infections or nosocomial pneumonia where methicillin or penicillin resistance is found are indicators for linezolid use. Compared to the older antibiotics it is quite expensive.

The drug works by inhibiting the initiation of bacterial protein synthesis; it is the only antibiotic to work in this manner. That and its synthetic nature raised hopes that bacteria would be unable to develop resistance to it and also remove the chance of cross-resistance. (However, in 1997 Staphylococcus aureus was first identified in Japan as being resistant to linezolid.) Linezolid is effective against gram-positive pathogens, notably Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes. It has almost no effect on gram-negative bacteria and is only bacteriostatic against most Enterococcus species.

The oxazolidinone class was discovered by researchers at E.I. duPont de Nemours and reported in 1987. Pharmacia Corporation developed linezolid and FDA approval was granted in April 2000. It is sold in the US under the tradename Zyvox in either tablet form, oral suspension powder, or in an inactive medium for intravenous injection.

Adverse effects

Side effects include rashes, loss of appetite, diarrhea, nausea, constipation and fever. A small number of patients will incur a severe allergic reaction, or tinnitis, or pseudomembranous colitis, or thrombocytopenia. Linezolid is a weak monoamine oxidase inhibitor (MAOI) and cannot be used with tyramine containing foods or pseudoephedrine.

Linezolid is toxic to mitochondria (probably because of the similarity of mitochondrial ribosomes to bacteria mitochondria). Signs of mitochondrial toxicity include lactic acidosis and peripheral neuropathy (Soriano et al., 2005).

Read more at Wikipedia.org


[List your site here Free!]


Zyvox
From Family Pratice News, 5/15/00 by Elizabeth Mechcatie

(linezolid, Pharmacia)

An antibacterial for adults with van-comycin-resistant Enterococcus faecium (VREF) infections, nosocomial pneumonia, and skin and skin structure infections (SSTIs), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA). Also for uncomplicated SSTIs and community-acquired pneumonia (CAP) caused by indicated bacteria. The first oxazolidinone antibiotic approved.

* Recommended Dosage: Intravenous or oral formulations every 12 hours; dose and treatment duration vary by infection.

* Special Considerations: Generally well tolerated; diarrhea, headache, nausea, and vomiting most common side effects. About 2% of subjects developed thrombocytopenia, which was associated with more than 2 weeks of treatment and was reversible in most patients.

* Comment: Zyvox investigator Dr. Dennis Stevens, chief of infectious diseases at the Veterans Affairs Medical Center, Boise, Idaho, called Zyvox an "excellent" drug for treating resistant or sensitive gram-positive bacteria, but said it should be used mainly in hospitals to treat known antibiotic-resistant gram-positive infections or in cases where physicians have "a high index of suspicion" a patient is infected with a resistant organism. An advantage is that Zyvox can be administered intravenously or orally, so patients can be sent home on one of the highly bioavailable oral formulations, added Dr. Stevens, who has received research grants from Pharmacia but has no other ties to the company.

Patients with VREF infections treated with Zyvox had a 67% cure rate in clinical trials. The FDA urges prescribers to "carefully consider alternatives" before using Zyvox in outpatients because of concerns about increasing resistant organisms.

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Zyvox
Home Contact Resources Exchange Links ebay